Caractérisation moléculaire et cellulaire du rôle de la poly(ADP-ribose) polymérase 3 (PARP3) dans la maintenance de l'intégrité du génome

Caractérisation moléculaire et cellulaire du rôle de la poly(ADP-ribose) polymérase 3 (PARP3) dans la maintenance de l'intégrité du génome

La poly(ADP-ribosyl)ation est une modification post-traductionnelle des protéines par les poly(ADP-ribose) polymérases (PARPs). PARP3 a été identifiée comme un nouvel acteur de la réparation des cassures double-brin (DSBs). Nous avons évalué la contribution de PARP3 dans les différentes voies de rép...

Full description

Bibliographic Details
Main Author:	Beck, Carole
Other Authors:	Strasbourg
Language:	fr
Published:	2016
Subjects:	PARP3 Ku80 BRCA1 53BP1 Modifications d’histones DSBs Centrosomes Cancer du sein Histone modifications Breast cancer 572.8 616.99
Online Access:	http://www.theses.fr/2016STRAJ075

Similar Items

Herpes Simplex Virus-type1 (HSV-1) Impairs DNA Repair in Cortical Neurons
by: Giovanna De Chiara, et al.
Published: (2016-10-01)

Differences of variable number tandem repeats in XRCC5 promoter are associated with increased or decreased risk of breast cancer in BRCA gene mutation carriers
by: Jian eCui, et al.
Published: (2016-04-01)

A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma
by: Alvaro Gonzalez Rajal, et al.
Published: (2021-05-01)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
by: Qianyan Li, et al.
Published: (2021-04-01)

Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
by: Katarzyna Kluzek, et al.
Published: (2012-06-01)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
by: Aniello Cerrato, et al.
Published: (2016-11-01)

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo
by: Colin Thomas, et al.
Published: (2016-11-01)

Etude de la Poly(ADP-ribosyl)ation dans un contexte des cassures double-brins des ADN nucléaire et mitochondriaux chez Drosophila melanogaster
by: Ishak, Layal
Published: (2016)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
by: Yingzhu Yang, et al.
Published: (2020-07-01)

PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
by: Valentina Perini, et al.
Published: (2020-11-01)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
by: Kristin eZorn, et al.
Published: (2016-04-01)

Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01)

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
by: Kathleen E. Fenerty, et al.
Published: (2018-11-01)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
by: Dawn C. Janysek, et al.
Published: (2021-03-01)

Analyse de la régulation de l'homéostasie des télomères et de la chromatine dans le maintien de l'intégrité génomique chez la levure Saccharomyces cerevisiae
by: Faucher, David
Published: (2010)

Moving Mountains—The BRCA1 Promotion of DNA Resection
by: Ruth M. Densham, et al.
Published: (2019-09-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study
by: Jolanta Hybiak, et al.
Published: (2019-01-01)

The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1
by: Kei Otsuka, et al.
Published: (2020-07-01)

Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018-08-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
by: Orazio Caffo, et al.
Published: (2018-09-01)

Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2
by: Tomoyuki Mukai, et al.
Published: (2019-02-01)

Understanding the role of ALC1-dependent chromatin remodeling in mediating PARP-inhibitor sensitivity
by: Deraska, Peter
Published: (2020)

Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold
by: Lingxiao Wang, et al.
Published: (2016-06-01)

X irradiation induced colonic mucosal injury and the detection of apoptosis through PARP-1/p53 regulatory pathway
by: Meryem Akpolat, et al.
Published: (2020-07-01)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
by: Gabriel S. Macedo, et al.
Published: (2019-04-01)

Cytotoxic and targeted therapy for BRCA1/2-driven cancers
by: Evgeny N. Imyanitov
Published: (2021-08-01)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
by: Chiho Kim, et al.
Published: (2020-08-01)

<i>BRCA1/2</i> Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
by: Ettore Capoluongo, et al.
Published: (2019-10-01)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
by: Zhimin Zhang, et al.
Published: (2020-01-01)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
by: Luyao Wang, et al.
Published: (2017-10-01)

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response
by: Aladdin Riad, et al.
Published: (2020-12-01)

Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy
by: Laura Keren Urbina-Jara, et al.
Published: (2019-10-01)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01)

53BP1 and BRCA1 control pathway choice for stalled replication restart
by: Yixi Xu, et al.
Published: (2017-11-01)

Regulation of the Anti-apoptotic Protein Ku70 and the Implications for Bax-Mediated Apoptosis
by: Gama, Vivian
Published: (2008)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-12-01)

The Sound of Silence: RNAi in Poly (ADP-Ribose) Research
by: Felix R. Althaus, et al.
Published: (2012-12-01)